MABT Appoints Professor Srinivasan Madhusudan to Scientific Advisory Board

News fromCourierPR · 1 min read

DOYLESTOWN, Pa., Nov. 17, 2026 /CourierPR/ -- MABT, a pharmaceutical company focused on developing and commercializing novel therapeutic approaches and AI-enabled technologies, has appointed Professor Srinivasan Madhusudan to its Scientific Advisory Board (SAB). This move underscores the company’s commitment to advancing its research in oncology and central nervous system (CNS) disorders.

Professor Madhusudan, a renowned expert in translational cancer research and DNA damage response (DDR) biology, brings extensive experience in precision medicine strategies targeting DNA repair vulnerabilities in cancer. He is currently the Professor of Medical Oncology at the University of Nottingham, UK, and the Director of the Naaz-Coker Ovarian Cancer Research Centre in the Biodiscovery Institute. His appointment is expected to provide invaluable scientific and translational guidance to MABT, enhancing the company’s research and development efforts.

David Horn, MABT’s Chief Executive Officer, expressed his delight at welcoming Professor Madhusudan to the SAB.

Professor Madhusudan's research integrates laboratory investigation of DNA damage signaling and repair with the identification of biomarkers, therapeutic targets, and personalized treatment strategies. His clinical research expertise spans breast, ovarian, and upper gastrointestinal cancers, complemented by substantial experience in cancer clinical trials and previous leadership of the Cancer Clinical Trials Unit at Nottingham University Hospitals and NHS Cancer Genomics. His published work encompasses base excision repair, PARP biology, DNA damage response signaling, and synthetic lethality, approaches that exploit specific DNA repair vulnerabilities in cancer cells. His research includes studies of APE1, XRCC1, and FEN1, as well as strategies involving ATR, ATM, and other DDR targets. These investigations connect tumor biology and biomarker evaluation with opportunities to address treatment resistance and develop more precisely targeted therapies.

In his advisory role, Professor Madhusudan is expected to provide scientific and translational guidance, with an emphasis on connecting target biology, preclinical evidence, and biomarker strategies to clinically relevant development questions. His appointment is seen as a significant step in MABT’s ongoing efforts to advance its research and development in the field of oncology and CNS disorders.

Start filing today

One press release free every week. No card required.

Create a free account